ELMMB logo
Facebook logo Twitter logo
Menu

2.0 Cardiovascular

2.0 Cardiovascular
 2.1 Positive inotropic drugs
 2.2 Diuretics
 2.3 Anti-arrhythmic drugs
 2.4 Beta-adrenoceptor blocking drugs
 2.5 Hypertension and Heart Failure
 2.6 Nitrates, calcium-channel blockers & other antianginal drugs
 2.7 Sympathomimetics
 2.8 Anticoagulants and Protamine
 2.9 Antiplatelet drugs
 2.10 Myocardial infarction and fibrinolysis
 2.11 Antifibrinolytic drugs and haemostatics
 2.12 Lipid regulating drugs
 2.13 Local sclerosants


Useful Guidelines and Information

MHRA Drug Safety Update: Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in 
                                                   patients with renal impairment [Published May 2023]
DOAC dosing in renal impairment - SPS 0919
Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline 
Isosorbide Mononitrate - Conversion to Modified Release ELHE
Tranexamic Acid Topical Use to control surface bleeding from fungating wounds in the skin
Ivabradine Prescribing Information Sheet v2.1
Omega 3 Fatty Acid Compounds v2.01
Clopidogrel for Stroke or Mini Stroke - Patient Information Leaflet
Ivabradine in chronic stable angina: Prescribing Guide for GP's
Ranolazine: Prescribing Guide for GP's


NICE Clinical Guidance
 NICE CG95      Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
 NICE NG106   Chronic heart failure in adults: diagnosis and management
 NICE NG136   Hypertension in adults: diagnosis and management
 NICE CG167    Myocardial infarction with ST-segment elevation: acute management
 NICE CG172    Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease
 NICE CG181    Cardiovascular disease: risk assessment and reduction, including lipid modification
 NICE CG182    Chronic kidney disease in adults: assessment and management
 NICE CG187    Acute heart failure: diagnosis and management